Hangzhou Tigermed Consulting Co., Ltd., commonly known as Tigermed, is a leading clinical research organisation headquartered in Hangzhou, China. Founded in 2004, the company has established a strong presence across Asia, Europe, and North America, providing comprehensive services in the pharmaceutical and biotechnology sectors. Tigermed specialises in clinical trial management, regulatory affairs, and data management, offering unique solutions that streamline the drug development process. With a commitment to quality and innovation, the company has achieved significant milestones, including numerous successful trials for global clients. Recognised for its expertise and reliability, Tigermed holds a prominent position in the industry, contributing to advancements in healthcare and supporting the development of new therapies. Its dedication to excellence has earned it a reputation as a trusted partner in clinical research.
How does Hangzhou Tigermed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Hangzhou Tigermed's score of 27 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Hangzhou Tigermed Consulting Co., Ltd. reported total carbon emissions of approximately 2,136,860 kg CO2e, with Scope 1 emissions at about 94,270 kg CO2e and Scope 2 emissions at around 2,042,580 kg CO2e. This reflects a commitment to transparency in their environmental impact, particularly in the pharmaceuticals, biotechnology, and life sciences sector. For the year 2022, their global emissions were approximately 2,163,020 kg CO2e, with Scope 1 emissions of about 84,210 kg CO2e and Scope 2 emissions of approximately 2,078,810 kg CO2e. In 2021, the company reported total emissions of about 1,438,920 kg CO2e, with Scope 1 at approximately 52,930 kg CO2e and Scope 2 at around 1,385,990 kg CO2e. Tigermed has committed to near-term climate targets, although they have not set a net-zero target as of now. Their ongoing efforts indicate a proactive approach to managing and reducing their carbon footprint, aligning with industry standards for climate action. The company continues to monitor and report its emissions, demonstrating a commitment to sustainability and environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|
Scope 1 | 63,180 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 |
Scope 2 | 1,037,878 | 0,000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 3 | - | - | - | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hangzhou Tigermed is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.